ArriVent BioPharma — Third Quarter 2026 Earnings Summary

ArriVent BioPharma reported third-quarter 2026 financial results showing a net loss of $133.5 million for the nine months ended September 30, 2026, with cash and investments totaling $393.2 million expected to fund operations through mid-2028. The company continued enrollment in its pivotal Phase 3 ALPACCA trial for firmonertinib in EGFR PACC-mutant NSCLC, while the Phase 3 FURVENT study did not meet its primary progression-free survival endpoint. In its antibody-drug conjugate pipeline, ArriVent presented encouraging Phase 1 data for ARR-217 in colorectal cancer and dosed the first patient in a Phase 1 study for the dual-target ADC ARR-002 in ovarian and endometrial cancers. Additionally, the company strengthened its leadership by appointing Dr. Priti Patel as Chief Medical Officer and announced the retirement of co-founder Dr. Stuart Lutzker.